Abstract
Obesity changes the regulatory mechanisms of the immune system, resulting in impaired immunity. In cancer immune mechanisms, the greater the degree of obesity, the lower the activity of the lymphocytes. Herein, we examined the relationship between obesity and lymphocytes in breast cancer patients undergoing chemotherapy. We recruited 10 recurrent or metastatic breast cancer patients who were administered eribulin. Using body mass index (BMI), we classified these patients into a non-obese group (BMK25) and an obese group (BMI>25). We measured the number of lymphocytes before chemotherapy and 8 days after eribulin administration. We examined the decreasing rates of lymphocytes before and after eribulin administration in the 2 groups. The average age was 63.1 years. Non-obese and obese groups comprised 6 and 4 cases, respectively. The average rates of lymphocyte decrease before and after eribulin administration were 13.3% and 12.3% in the non-obese and obese groups, respectively. There were no significant differences between the 2 groups.
Original language | English |
---|---|
Pages (from-to) | 1246-1248 |
Number of pages | 3 |
Journal | Japanese Journal of Cancer and Chemotherapy |
Volume | 43 |
Issue number | 10 |
Publication status | Published - Oct 2016 |
Keywords
- Chemotherapy
- Lymphocyte
- Obesity